Gilead Sciences, Inc. (NASDAQ:GILD) EVP Brett A. Pletcher sold 5,000 shares of the company’s stock in a transaction dated Thursday, February 6th. The shares were sold at an average price of $68.18, for a total value of $340,900.00. Following the completion of the sale, the executive vice president now directly owns 29,690 shares of the company’s stock, valued at $2,024,264.20. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Gilead Sciences stock opened at $66.95 on Thursday. Gilead Sciences, Inc. has a twelve month low of $60.89 and a twelve month high of $71.19. The stock has a 50 day moving average of $65.10 and a two-hundred day moving average of $64.95. The company has a current ratio of 3.23, a quick ratio of 3.01 and a debt-to-equity ratio of 1.11. The stock has a market capitalization of $84.70 billion, a price-to-earnings ratio of 15.90, a PEG ratio of 4.92 and a beta of 1.21.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $1.30 earnings per share for the quarter, missing analysts’ consensus estimates of $1.67 by ($0.37). Gilead Sciences had a return on equity of 35.49% and a net margin of 23.99%. The company had revenue of $5.88 billion for the quarter, compared to analyst estimates of $5.74 billion. During the same period in the previous year, the business posted $1.44 earnings per share. The firm’s revenue was up 1.4% compared to the same quarter last year. Equities analysts predict that Gilead Sciences, Inc. will post 6.12 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be given a dividend of $0.68 per share. This represents a $2.72 dividend on an annualized basis and a yield of 4.06%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.63. The ex-dividend date of this dividend is Thursday, March 12th. Gilead Sciences’s dividend payout ratio (DPR) is presently 41.04%.
A number of brokerages recently issued reports on GILD. Credit Suisse Group upped their target price on Gilead Sciences from $59.00 to $60.00 and gave the company an “underperform” rating in a research report on Wednesday, February 5th. BidaskClub raised Gilead Sciences from a “strong sell” rating to a “sell” rating in a research report on Wednesday, February 5th. Raymond James cut Gilead Sciences from a “strong-buy” rating to an “outperform” rating and decreased their target price for the company from $81.00 to $80.00 in a research report on Wednesday, February 5th. Sanford C. Bernstein cut Gilead Sciences from an “outperform” rating to a “market perform” rating and decreased their target price for the company from $78.00 to $70.00 in a research report on Thursday, February 6th. Finally, Piper Sandler decreased their target price on Gilead Sciences from to in a research report on Wednesday, February 5th. Three research analysts have rated the stock with a sell rating, eleven have issued a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $77.79.
Institutional investors have recently bought and sold shares of the business. Knuff & Co LLC raised its stake in shares of Gilead Sciences by 2.3% during the 3rd quarter. Knuff & Co LLC now owns 34,310 shares of the biopharmaceutical company’s stock worth $2,175,000 after buying an additional 770 shares in the last quarter. AMG National Trust Bank raised its stake in shares of Gilead Sciences by 8.5% during the 4th quarter. AMG National Trust Bank now owns 74,817 shares of the biopharmaceutical company’s stock worth $4,862,000 after buying an additional 5,861 shares in the last quarter. S.A. Mason LLC purchased a new position in shares of Gilead Sciences during the 4th quarter worth approximately $60,000. Ackerman Capital Advisors LLC raised its stake in shares of Gilead Sciences by 71.4% during the 4th quarter. Ackerman Capital Advisors LLC now owns 6,000 shares of the biopharmaceutical company’s stock worth $390,000 after buying an additional 2,500 shares in the last quarter. Finally, Fulcrum Capital LLC purchased a new position in shares of Gilead Sciences during the 3rd quarter worth approximately $9,804,000. 79.26% of the stock is owned by institutional investors.
About Gilead Sciences
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Further Reading: What is a back-end load?
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.